Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TELA Bio (TELA) Share-based Compensation (2018 - 2025)

Historic Share-based Compensation for Bio (TELA) over the last 8 years, with Q3 2025 value amounting to $955000.0.

  • Bio's Share-based Compensation fell 1165.59% to $955000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $4.1 million, marking a year-over-year decrease of 976.96%. This contributed to the annual value of $4.4 million for FY2024, which is 1331.48% down from last year.
  • Bio's Share-based Compensation amounted to $955000.0 in Q3 2025, which was down 1165.59% from $985000.0 recorded in Q2 2025.
  • Over the past 5 years, Bio's Share-based Compensation peaked at $1.4 million during Q2 2021, and registered a low of $694000.0 during Q1 2021.
  • In the last 5 years, Bio's Share-based Compensation had a median value of $1.0 million in 2025 and averaged $1.1 million.
  • Its Share-based Compensation has fluctuated over the past 5 years, first soared by 18583.0% in 2021, then plummeted by 2762.04% in 2022.
  • Bio's Share-based Compensation (Quarter) stood at $822000.0 in 2021, then rose by 26.4% to $1.0 million in 2022, then grew by 19.44% to $1.2 million in 2023, then decreased by 12.25% to $1.1 million in 2024, then decreased by 12.3% to $955000.0 in 2025.
  • Its last three reported values are $955000.0 in Q3 2025, $985000.0 for Q2 2025, and $1.0 million during Q1 2025.